Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
ORIGINAL ARTICLE
Year : 2020  |  Volume : 33  |  Issue : 3  |  Page : 778-782

Hematological and biochemical changes due to anti-hepatitis C virus therapy


1 Department of Internal Medicine, Faculty of Medicine, Menoufia University, Menoufia, Egypt
2 Menoufia Hepatology Center, Menoufia, Egypt

Correspondence Address:
Baher E Maadawi Radi
Shabas Elshouhada, Dessouq, Kafr Al Sheikh 32717
Egypt
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/mmj.mmj_398_18

Rights and Permissions

Objective The aim of the study was to assess the hematological and biochemical changes in patients who have received anti-hepatitis C virus (HCV) therapy before treatment and follow-up after 3 months of treatment as regards the advantages and disadvantages through a follow up of the studied patients. Background There is a dramatic improvement in HCV therapy following the introduction of oral medicines that directly inhibit the replication cycle of HCV, so the follow up of patients who are receiving therapy before and 6 months after treatment is mandatory to choose the best drug for each patient with the least side effects. Patients and methods This study was done on 200 patients admitted to the Kafr El-Sheikh Hepatology Center diagnosed as HCV-infected patients. Those patients were classified according to the Child classification as Child A score 6. Of them, 100 patients received sofosbuvir + ledipasvir and another 100 patients received sofosbuvir + daclatasvir, respectively. All patients were subjected to the following investigations before and 6 months after treatment: complete blood count, biochemical investigations including serum albumin, alanine transaminase, aspartate transaminase, random blood sugar, blood urea, serum creatinine, total and direct bilirubin, and alkaline phosphatase, thyroid-stimulating hormone level, alpha-fetoprotein, and antinuclear antibody. Results All the previous laboratory investigations were done to all 200 patients, recorded and compared before treatment and 6 months after treatment. Conclusion Ledipasvir and sofosbuvir for 8 weeks or 12 weeks is a highly effective treatment option for the treatment of hepatitis C-infected patients and give best results more than sofosbuvir and daclatasvir.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed34    
    Printed0    
    Emailed0    
    PDF Downloaded5    
    Comments [Add]    

Recommend this journal